The U.S. Food and Drug Administration approved Rasonque, a once-daily pill for late-stage pancreatic cancer patients who failed prior treatments, on Wednesday.
This approval provides a new therapeutic option for a patient population facing extremely high mortality rates. Advanced pancreatic cancer is historically difficult to treat, with 97% of patients dying within five years [4].
Rasonque, also known by its generic name daraxonrasib, is a KRAS-targeting drug. It works by inhibiting the KRAS-driven tumor mechanism to slow cancer progression. This specific protein is a driver in 95% of pancreatic adenocarcinoma cases [3].
Clinical data indicates that survival time for patients using the drug doubled compared with chemotherapy alone [1]. Other reports confirm that patient survival rates nearly double when using the treatment [2].
The FDA granted the approval more than six months ahead of its original target date [5]. The drug is intended for use after standard chemotherapy has failed to produce a response.
Pancreatic cancer often remains undetected until it reaches an advanced stage. Because the KRAS protein is so prevalent in these tumors, the drug targets a primary mechanism of the disease across a vast majority of cases [3].
“Survival time doubled compared with chemotherapy alone”
The approval of Rasonque represents a shift toward precision medicine in oncology. By targeting the KRAS protein, a mutation long considered 'undruggable', the FDA is expanding the toolkit for one of the deadliest forms of cancer. While the drug is reserved for late-stage patients who have exhausted other options, the significant increase in survival time suggests a new benchmark for palliative and extended-life care in pancreatic adenocarcinoma.
